Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RecruitingNot applicableNCT07080788
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this pilot study is to assess whether 4-weeks of verified smoking abstinence following financial incentive treatment for smoking cessation improves physiological markers of chronic pain risk in adult Native American smokers. The main aims to answer are: 1. Determine study feasibility. 2. Obtain effect sizes for changes in pain amplification and pain inhibition in abstinent vs non-abstinent Native Americans. 3. Obtain effect sizes for variables in the conceptual model of the Native American smoking-pain relationship.
Study details
- Official title
- Can Smoking Cessation Improve Physiological Markers of Chronic Pain Risk in Native American Smokers?: A Pilot Feasibility Study
- Conditions
- Smoking Cessation Intervention
- Pain
- Smoking (Tobacco) Addiction
- Interventions
- Behavioral: Smoking Cessation
- Sponsor
- University of Oklahoma
- Start date
- 2025-09-01
- Primary completion
- 2027-06
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Self-identify as Native American/American Indian * Currently daily smoker * Own a smartphone with a data plan * Ability to speak and read English Exclusion Criteria: * \>18 years of age * Currently pregnant * Self-reported history of heart disease or heart attack * Angina, arrhythmias, hypertension, heart disease * Current chronic pain * Pepper allergy * Inability to speak English * Current psychosis (assessed by Psychosis Screening Questionnaire) * Serious cognitive impairment (assessed by \<20 score on the Montreal Cognitive Assessment \[MoCA\])
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07080788